Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
NCT ID: NCT04895410
Last Updated: 2023-03-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1
8 participants
INTERVENTIONAL
2022-01-17
2022-06-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Lemzoparlimab is an investigational drug being developed for the treatment of relapsed/refractory (R/R) MM. Study doctors put the participants in groups called treatment arms. Two different dose levels of lemzoparlimab will be explored. Each treatment arm receives a different treatment combination depending on stage of the study and eligibility. This study will include a dose escalation phase to determine the best dose of lemzoparlimab, followed by a dose expansion phase to confirm the dose. Approximately 163 adult participants with R/R MM will be enrolled in the study in approximately 60 sites worldwide.
In the Dose Escalation arms, participants will receive intravenous (IV) lemzoparlimab with or without dexamethasone (oral/IV) in combination with pomalidomide (oral) or carfilzomib (IV) or subcutaneous (SC) daratumumab in 28-day cycles. In the Dose Expansion arms, participants will receive lemzoparlimab (IV) alone or with dexamethasone (oral/IV) in combination with pomalidomide (oral) or carfilzomib (IV) or daratumumab (SC) in 28-day cycles.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests and side effects.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma
NCT02252172
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
NCT07095452
Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00772915
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
NCT04268498
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
NCT06932562
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose Escalation: Lemzoparlimab
Participants will receive lemzoparlimab in 28 day cycles.
Lemzoparlimab
Intravenous (IV) infusion
Dose Escalation: Lemzoparlimab + Pomalidomide + Dexamethasone
Participants will receive lemzoparlimab + pomalidomide + dexamethasone in 28 day cycles.
Lemzoparlimab
Intravenous (IV) infusion
Dexamethasone
Oral tablet or IV infusion/injection
Pomalidomide
Oral capsule
Dose Escalation: Lemzoparlimab + Carfilzomib + Dexamethasone
Participants will receive lemzoparlimab + carfilzomib + dexamethasone in 28 day cycles.
Lemzoparlimab
Intravenous (IV) infusion
Dexamethasone
Oral tablet or IV infusion/injection
Carfilzomib
IV infusion
Dose Escalation: Lemzoparlimab + Daratumumab + Dexamethasone
Participants will receive lemzoparlimab + daratumumab + dexamethasone in 28 day cycles.
Lemzoparlimab
Intravenous (IV) infusion
Dexamethasone
Oral tablet or IV infusion/injection
Daratumumab
Subcutaneous (SC) injection
Dose Expansion: Lemzoparlimab
Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion in 28 day cycles.
Lemzoparlimab
Intravenous (IV) infusion
Dose Expansion: Lemzoparlimab + Dexamethasone
Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion + dexamethasone in 28 day cycles.
Lemzoparlimab
Intravenous (IV) infusion
Dexamethasone
Oral tablet or IV infusion/injection
Dose Expansion: Lemzoparlimab + Pomalidomide + Dexamethasone
Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion + pomalidomide + dexamethasone in 28 day cycles.
Lemzoparlimab
Intravenous (IV) infusion
Dexamethasone
Oral tablet or IV infusion/injection
Pomalidomide
Oral capsule
Dose Expansion: Lemzoparlimab + Carfilzomib + Dexamethasone
Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion + carfilzomib + dexamethasone in 28 day cycles.
Lemzoparlimab
Intravenous (IV) infusion
Dexamethasone
Oral tablet or IV infusion/injection
Carfilzomib
IV infusion
Dose Expansion: Lemzoparlimab + Daratamumab + Dexamethasone
Participants will receive lemzoparlimab at recommended dose determined in Dose Escalation portion + daratamumab + dexamethasone in 28 day cycles.
Lemzoparlimab
Intravenous (IV) infusion
Dexamethasone
Oral tablet or IV infusion/injection
Daratumumab
Subcutaneous (SC) injection
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lemzoparlimab
Intravenous (IV) infusion
Dexamethasone
Oral tablet or IV infusion/injection
Carfilzomib
IV infusion
Pomalidomide
Oral capsule
Daratumumab
Subcutaneous (SC) injection
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Relapsed defined as previously treated myeloma that progresses and requires initiation of salvage therapy, but does not meet criteria for refractory myeloma.
* Refractory defined as disease that is nonresponsive (failure to achieve minimal response or development of progressive disease) while on primary or salvage therapy, or progresses within 60 days of last therapy.
* Measurable disease per the protocol within 28 days prior to enrollment.
* Arm A - Lemzoparlimab with or without Dexamethasone
* For Both Escalation and Expansion Phase, participant must have refractory to 3 prior lines of treatment of anti-myeloma treatments, as outlined in the protocol.
* Arm B - Lemzoparlimab + Pomalidomide-Dexamethasone
* For Escalation Phase - Participant must have received at least 3 prior lines of therapy, as outlined in the protocol.
* For Expansion Phase- Participant must have received at least 2 prior line of therapy, as outlined in the protocol.
* Arm C - Lemzoparlimab + Carfilzomib-Dexamethasone
* For Escalation Phase- Participant must have received at least 3 prior lines of therapy as outlined in the protocol.
* For Expansion Phase- Participant must have received at least 1 prior line of therapy.
* Arm D - Lemzoparlimab + Daratumumab-Dexamethasone -- For Both Escalation and Expansion Phase - Participant must: --- Have received at least 3 prior lines of therapy, as outlined in the protocol.
Exclusion Criteria
* For Both Escalation and Expansion Phase participant must have had no prior treatment with pomalidomide.
* Arm C - Lemzoparlimab + Carfilzomib-Dexamethasone
* For Both Escalation and Expansion Phase - prior treatment with carfilzomib.
* Arm D - Lemzoparlimab + Daratumumab-Dexamethasone
* For Both Escalation and Expansion Phase - prior treatment with daratumumab or other anti-CD38 therapy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sylvester Comprehensive Cancer Center /ID# 228817
Miami, Florida, United States
Moffitt Cancer Center /ID# 229939
Tampa, Florida, United States
Norton Cancer Institute - St Matthews /ID# 229319
Louisville, Kentucky, United States
Tulane Cancer Center Clinic /ID# 229832
New Orleans, Louisiana, United States
University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 229309
Ann Arbor, Michigan, United States
Henry Ford Health System /ID# 230341
Detroit, Michigan, United States
Rutgers Cancer Institute of New Jersey /ID# 230174
New Brunswick, New Jersey, United States
Columbia University Medical Center /ID# 229971
New York, New York, United States
Duke University Hospital /ID# 229564
Durham, North Carolina, United States
Wake Forest Baptist Health /ID# 229996
Winston-Salem, North Carolina, United States
Perelman Center for Advanced Medicine - /ID# 228693
Philadelphia, Pennsylvania, United States
University of Virginia /ID# 229396
Charlottesville, Virginia, United States
The Queen Elizabeth Hospital /ID# 229345
Woodville South, South Australia, Australia
Alfred Health /ID# 229347
Melbourne, Victoria, Australia
HCL - Hôpital Lyon Sud /ID# 229834
Pierre-Bénite, Auvergne-Rhône-Alpes, France
CHU de Nantes, Hotel Dieu -HME /ID# 228559
Nantes, Pays de la Loire Region, France
CHU Poitiers - La milétrie /ID# 229833
Poitiers, Poitou-Charentes, France
Hopital Henri Mondor /ID# 228562
Créteil, , France
Asklepios Klinik Altona /ID# 229143
Hamburg, , Germany
The Chaim Sheba Medical Center /ID# 229483
Ramat Gan, Tel Aviv, Israel
Tel Aviv Sourasky Medical Center /ID# 229478
Tel Aviv, Tel Aviv, Israel
Rambam Health Care Campus /ID# 229485
Haifa, , Israel
Hadassah Medical Center-Hebrew University /ID# 229477
Jerusalem, , Israel
Meir Medical Center /ID# 229480
Kfar Saba, , Israel
Rabin Medical Center /ID# 229488
Petah Tikva, , Israel
University Hospital Kyoto Prefectural University of Medicine /ID# 241833
Kyoto, Kyoto, Japan
Hospital Clínico Universitario de Santiago-CHUS /ID# 229356
Santiago de Compostela, A Coruna, Spain
Hospital Unversitario Marques de Valdecilla /ID# 229354
Santander, Cantabria, Spain
Hospital Parc de Salut del Mar /ID# 229371
Barcelona, , Spain
Hospital Santa Creu i Sant Pau /ID# 229369
Barcelona, , Spain
Hospital Universitario Reina Sofia /ID# 229388
Córdoba, , Spain
Hospital Universitario 12 de Octubre /ID# 229355
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-001067-24
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
M20-917
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.